Improving outcomes of first-episode psychosis: an overview

被引:181
作者
Fusar-Poli, Paolo [1 ,2 ]
McGorry, Patrick D. [3 ,4 ]
Kane, John M. [5 ,6 ,7 ]
机构
[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, Early Psychosis Intervent & Clin Detect Lab, London, England
[2] South London & Maudsley NHS Fdn Trust, OASIS Serv, London, England
[3] Orygen, Parkville, Vic, Australia
[4] Univ Melbourne, Ctr Youth Mental Hlth, Melbourne, Vic, Australia
[5] Zucker Hillside Hosp, Glen Oaks, NY USA
[6] Hofstra Northwell Sch Med, Dept Psychiat, Hempstead, NY USA
[7] Hofstra Northwell Sch Med, Dept Mol Med, Hempstead, NY USA
关键词
Psychosis; schizophrenia; psychosis risk; clinical high risk; first episode psychosis; universal prevention; selective prevention; indicated prevention; outcomes; clinical staging; CLINICAL HIGH-RISK; ULTRA-HIGH RISK; RANDOMIZED-CONTROLLED-TRIAL; ACTING INJECTABLE ANTIPSYCHOTICS; 1ST EPISODE PSYCHOSIS; 10-YEAR FOLLOW-UP; EARLY INTERVENTION; TREATMENT RESPONSE; UNTREATED PSYCHOSIS; ORAL ANTIPSYCHOTICS;
D O I
10.1002/wps.20446
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Outcomes of psychotic disorders are associated with high personal, familiar, societal and clinical burden. There is thus an urgent clinical and societal need for improving those outcomes. Recent advances in research knowledge have opened new opportunities for ameliorating outcomes of psychosis during its early clinical stages. This paper critically reviews these opportunities, summarizing the state-of-the-art knowledge and focusing on recent discoveries and future avenues for first episode research and clinical interventions. Candidate targets for primary universal prevention of psychosis at the population level are discussed. Potentials offered by primary selective prevention in asymptomatic subgroups (stage 0) are presented. Achievements of primary selected prevention in individuals at clinical high risk for psychosis (stage 1) are summarized, along with challenges and limitations of its implementation in clinical practice. Early intervention and secondary prevention strategies at the time of a first episode of psychosis (stage 2) are critically discussed, with a particular focus on minimizing the duration of untreated psychosis, improving treatment response, increasing patients' satisfaction with treatment, reducing illicit substance abuse and preventing relapses. Early intervention and tertiary prevention strategies at the time of an incomplete recovery (stage 3) are further discussed, in particular with respect to addressing treatment resistance, improving well-being and social skills with reduction of burden on the family, treatment of comorbid substance use, and prevention of multiple relapses and disease progression. In conclusion, to improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is necessary to globally adopt complex models integrating a clinical staging framework and coordinated specialty care programmes that offer pre-emptive interventions to high-risk groups identified across the early stages of the disorder. Only a systematic implementation of these models of care in the national health care systems will render these strategies accessible to the 23 million people worldwide suffering from the most severe psychiatric disorders.
引用
收藏
页码:251 / 265
页数:15
相关论文
共 181 条
[1]   An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis [J].
Agid, Ofer ;
Arenovich, Tamara ;
Sajeev, Gautam ;
Zipursky, Robert B. ;
Kapur, Shitij ;
Foussias, George ;
Remington, Gary .
JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (11) :1439-1444
[2]   Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era [J].
Alvarez-Jimenez, M. ;
O'Donoghue, B. ;
Thompson, A. ;
Gleeson, J. F. ;
Bendall, S. ;
Gonzalez-Blanch, C. ;
Killackey, E. ;
Wunderink, L. ;
McGorry, P. D. .
CNS DRUGS, 2016, 30 (05) :357-368
[3]   Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis [J].
Alvarez-Jimenez, Mario ;
Parker, Alexandra G. ;
Hetrick, Sarah E. ;
McGorry, Patrick D. ;
Gleeson, John F. .
SCHIZOPHRENIA BULLETIN, 2011, 37 (03) :619-630
[4]  
Ando S, 2016, EARLY INTERV PSYCHIA, V8, P1
[5]   Relapse Duration, Treatment Intensity, and Brain Tissue Loss in Schizophrenia: A Prospective Longitudinal MRI Study (vol 170, pg 609, 2013) [J].
Andreasen, Nancy C. .
AMERICAN JOURNAL OF PSYCHIATRY, 2013, 170 (06) :689-689
[6]   Remission in schizophrenia: Proposed criteria and rationale for consensus [J].
Andreasen, NC ;
Carpenter, WT ;
Kane, JM ;
Lasser, RA ;
Marder, SR ;
Weinberger, DR .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) :441-449
[7]  
[Anonymous], PSYCH SCHIZ AD PREV
[8]  
[Anonymous], 2004, Prevention of mental disorders: Effective interventions and policy options: A summary report
[9]   Infectious agents associated with schizophrenia: A meta-analysis [J].
Arias, Isabel ;
Sorlozano, Antonio ;
Villegas, Enrique ;
de Dios Luna, Juan ;
McKenney, Kathryn ;
Cervilla, Jorge ;
Gutierrez, Blanca ;
Gutierrez, Jose .
SCHIZOPHRENIA RESEARCH, 2012, 136 (1-3) :128-136
[10]   Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10 year follow-up study in the OPUS cohort [J].
Austin, Stephen F. ;
Mors, Ole ;
Budtz-Jorgensen, Esben ;
Secher, Rikke Gry ;
Hjorthoj, Carsten R. ;
Bertelsen, Mette ;
Jeppesen, Pia ;
Petersen, Lone ;
Thorup, Anne ;
Nordentoft, Merete .
SCHIZOPHRENIA RESEARCH, 2015, 168 (1-2) :84-91